325 filings
Page 5 of 17
8-K
gb9o9ue4806
29 May 20
Entry into a Material Definitive Agreement
5:07pm
8-K
00yce
18 May 20
Other Events
4:45pm
8-K
raucfd
18 May 20
Regulation FD Disclosure
3:16pm
8-K
wuh3yucvp9r5tb 19
15 May 20
Novavax to Receive up to $388 Million Funding from CEPI
5:27pm
8-K
a5h12nco5biyh38jjrf
12 May 20
Novavax Reports First Quarter 2020 Financial Results
4:12pm
8-K
0hf8ikjvsz 3teiyf
24 Mar 20
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
4:15pm
8-K
mwny8h6d22yo ovk8ye
12 Mar 20
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
4:48pm
8-K
i1q i9nmo
2 Mar 20
Other Events
8:00am
8-K
b0kkgb
21 Jan 20
Other Events
5:08pm
8-K
pygn14fh7jwv11
8 Nov 19
Novavax Reports Third Quarter 2019 Financial Results
4:16pm
8-K
skwfg09un wsz
9 Sep 19
Other Events
5:03pm
8-K
tc43 h2kojper641qcuu
8 Aug 19
Novavax Reports Second Quarter 2019 Financial Results
4:15pm
8-K
4z0v4c
1 Aug 19
Novavax and Catalent Announce Closing of Strategic Partnership
4:28pm
8-K
9e1srpqhy
2 Jul 19
Submission of Matters to a Vote of Security Holders
4:34pm
8-K
tv4kagg 4a5dft
1 Jul 19
Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
4:23pm
8-K
z1xc a9519vil0w
9 May 19
Amendments to Articles of Incorporation or Bylaws
4:28pm
8-K
17b9hvnq
3 May 19
Novavax Reports First Quarter 2019 Financial Results
4:23pm
8-K
nws6x4y40hnnf
2 May 19
Entry into a Material Definitive Agreement
5:20pm
8-K
a0qags0 zgdaorow
18 Apr 19
Regulation FD Disclosure
4:10pm
8-K
0j0u9 qaoc6g3lmggckz
12 Apr 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:26pm